RGS14

Across TCGA pan-cancer cohorts, RGS14 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated RGS14 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RGS14 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RGS14 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where RGS14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	1.000	0.334	<.001	34	view →
LUAD	OS	Median	III,IV	0.747	1.000	.002	15	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	9	view →
OV	DFS	Median	All	0.942	0.622	.032	8	view →
UCEC	DFS	Tertile	III,IV	0.503	1.000	.049	4	view →
GBM	OS	Quartile	All	0.940	0.670	.015	2	view →
HNSC	OS	Median	II,III,IV	0.952	1.000	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RGS14–CCRCC (DFS)

Open the CCRCC breakdown →